Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
40.74
+0.87 (2.18%)
At close: Aug 13, 2025, 4:00 PM
40.73
-0.01 (-0.02%)
After-hours: Aug 13, 2025, 4:20 PM EDT
Kymera Therapeutics Revenue
Kymera Therapeutics had revenue of $11.48M in the quarter ending June 30, 2025, a decrease of -55.26%. This brings the company's revenue in the last twelve months to $44.71M, down -49.51% year-over-year. In the year 2024, Kymera Therapeutics had annual revenue of $47.07M, down -40.11%.
Revenue (ttm)
$44.71M
Revenue Growth
-49.51%
P/S Ratio
72.18
Revenue / Employee
$237,824
Employees
188
Market Cap
2.91B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
KYMR News
- 1 day ago - The Best Small-Cap Stocks to Buy Now - Kiplinger
- 2 days ago - Kymera Therapeutics, Inc. (KYMR) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update - GlobeNewsWire
- 6 weeks ago - Kymera Therapeutics Announces Pricing of $250 Million Public Offering - GlobeNewsWire
- 7 weeks ago - Kymera Therapeutics Announces Proposed Public Offering - GlobeNewsWire
- 7 weeks ago - Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics - Reuters
- 7 weeks ago - Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update - GlobeNewsWire
- 7 weeks ago - Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders - Business Wire